Oral Biologics MarketSize and Trends

The global oral biologics market is estimated to be valued at US$ 2.62 Bn in 2023 and is expected to exhibit a CAGR of 35.4% during the forecast period (2023-2030).

Figure 1. Global Oral Biologics Market Share (%), By Drug Type, 2023

Global Oral Biologics Market– Drivers

Increasing prevalence of diabetes: The increasing prevalence of diabetes worldwide is expected to drive the market growth over the forecast period. For instance, according to an article published by the WHO (World Health Organization) in April 2023, diabetes cases increased from 108 million in 1980 to 422 million in 2014. Prevalence has risen faster in low- and middle-income countries than in high-income countries. Furthermore, according to the same source, diabetes caused a 3% increase in age-standardized death rates between 2000 and 2019. Diabetes-related mortality increased by 13% in lower-middle-income countries.
Increasing research and development activities: Increasing research and development activities regarding oral biologics by market players is also expected to boost the global oral biologics market over the forecast period. For instance, in February 2023, Intralytix, Inc., a biotechnology company, initiated study on the safety and efficacy of oral biologic VRELysin in the treatment of Vancomycin-resistant enterococcal colonization. The study is in phase 2 of clinical trila and is expected to be completed in March 2025.

Figure 2. Global Oral Biologics Market Share(%), By Region, 2023

Market Trends: The rising number of patients with diabetes, hyperoxaluria, acromegaly, irritable bowel syndrome (IBS), and chronic idiopathic constipation for whom oral biologics are used for treatment. Thus, it offers the opportunity for various manufacturers to offer various oral biologics to treat these diseases.

Global Oral Biologics Market Segmentation:

The global oral biologics market report is segmented by drug class, by disease indication, by distribution channel, and by region.

By Drug Class , the market is segmented into glucagon-like peptide 1 (GLP-1) receptor agonist, hormone, recombinant enzyme, guanylate cyclase-C agonist, somatostatin analogue, and others. Out of which, the hormone is expected to hold a dominant position in the global oral biologics market during the forecast period, and this is attributed to the increasing product launches.
By Disease Indication, the market is segmented into diabetes, hyperoxaluria, acromegaly, irritable bowel syndrome (IBS) & chronic idiopathic constipation (CIC), and others (inflammatory bowel disease (IBD), hypoparathyroidism, and others. Out of which, diabetes is expected to dominate the market over the forecast period, and this is attributed to the increasing prevalence of diabetes.
By Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, retail pharmacies is expected to dominate the market over the forecast period, and this is attributed to the launch of new retail pharmacies.

Among all the segmentation, the disease indication segment is expected to dominate the market over the forecast period, and this is attributed to the increasing prevalence of different diseases.

Global Oral Biologics Market- Cross Sectional Analysis:

In drug class, hormone segment is expected to dominate the market in the North America region, and this is attributable to the increasing product approvals from regulatory authorities. For instance, in December 2020, Myovant Sciences, a biopharmaceutical company, announced that the U.S. FDA approved Orgovyx (relugolix), the first oral hormone therapy for treating advanced prostate cancer.

Global Oral Biologics Market: Key Trends

Increasing number of partnerships between the key market players

An increasing number of partnerships between the key market players is expected to boost market growth over the forecast period. For instance, in June 2023, Rani Therapeutics Holdings, Inc. announced that the company had extended its existing partnership with Celltrion, a biopharmaceutical company, by entering into an agreement for the development of RT-105, an orally administered adalimumab biosimilar.